抗逆转录病毒治疗对艾滋病患者脑灰质体积的影响

doi:10.11938/cjmr20202843

摘要/Abstract

摘要： 磁共振影像学研究表明艾滋病患者的脑结构发生了变化．虽然联合抗逆转录病毒治疗（combined antiretroviraltherapy，cART）能提高艾滋病患者的长期生存率，但是cART对艾滋病患者脑结构改变的影响并不清楚．本研究利用三维高分辨脑结构磁共振成像（magnetic resonance imaging，MRI）技术，使用基于体素的形态测量学方法，探讨了cART对艾滋病患者脑灰质体积的影响．本研究表明cART可以有效减少艾滋病患者的异常脑结构，提示早期实施cART的重要性．

关键词: 磁共振成像(MRI), 艾滋病, 联合抗逆转录病毒治疗(cART), 灰质体积

Abstract: Magnetic resonance imaging (MRI) studies have documented that there were structural abnormalities in acquired immune deficiency syndrome (AIDS) patients. Although the long-term survival rate of AIDS patients can be improved by the combined antiretroviral therapy (cART), little is known about the effect of cART on brain structural alterations in AIDS patients. In this study, three-dimensional high-resolution brain structure MRI and voxel-based morphometric methods were used to explore the effects of cART on brain gray matter volume in AIDS patients. The results indicate that cART may effectively mitigate the occurrence of abnormal brain structure in AIDS patients, emphasizing the importance of early initiation of cART.

Key words: magnetic resonance imaging (MRI), AIDS, combined antiretroviral therapy (cART), gray matter volume

中图分类号:

O482.53

辛红涛, 吴光耀, 文之, 雷皓, 林富春. 抗逆转录病毒治疗对艾滋病患者脑灰质体积的影响[J]. 波谱学杂志, 2021, 38(1): 69-79.

XIN Hong-tao, WU Guang-yao, WEN Zhi, LEI Hao, LIN Fu-chun. Effects of Antiretroviral Therapy on Brain Gray Matter Volumes in AIDS Patients[J]. Chinese Journal of Magnetic Resonance, 2021, 38(1): 69-79.

参考文献

[1] UNAIDS. AIDS epidemic update[OL]. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf. 2020.
[2] DALGLEISH A G. The pathogenesis of AIDS:classical and alternative views[J]. J R Coll Physicians Lond, 1992, 26(2):152-158.
[3] TSIBRIS A M, HIRSCH M S. Antiretroviral therapy in the clinic[J]. J Virol, 2010, 84(11):5458-5464.
[4] PALELLA JR F J, DELANEY K M, MOORMAN A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators[J]. N Engl J Med, 1998, 338(13):853-860.
[5] GONZÁLEZ-SCARANO F, MARTÍN-GARCÍA J. The neuropathogenesis of AIDS[J]. Nat Rev Immunol, 2005, 5(1):69-81.
[6] BHASKARAN K, MUSSINI C, ANTINORI A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy[J]. Ann Neurol, 2008, 63(2):213-221.
[7] ELLERO J, LUBOMSKI M, BREW B. Interventions for neurocognitive dysfunction[J]. Curr HIV/AIDS Rep, 2017, 14(1):8-16.
[8] ELBIRT D, MAHLAB-GURI K, BEZALEL-ROSENBERG S, et al. HIV-associated neurocognitive disorders (HAND)[J]. Isr Med Assoc J, 2015, 17(1):54-59.
[9] HEATON R K, CLIFFORD D B, FRANKLIN JR D R, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy:CHARTER Study[J]. Neurology, 2010, 75(23):2087-2096.
[10] ELLIS R J, DEUTSCH R, HEATON R K, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San diego HIV neurobehavioral research center group[J]. Arch Neurol, 1997, 54(4):416-424.
[11] RAGIN A B, DU H Y, OCHS R, et al. Structural brain alterations can be detected early in HIV infection[J]. Neurology, 2012, 79(24):2328-2334.
[12] WANG B, LIU Z Y, LIU J J, et al. Gray and white matter alterations in early HIV-infected patients:Combined voxel-based morphometry and tract-based spatial statistics[J]. J Magn Reson Imaging, 2016, 43(6):1474-1483.
[13] RAGIN A B, WU Y, GAO Y, et al. Brain alterations within the first 100 days of HIV infection[J]. Ann Clin Transl Neurol, 2015, 2(1):12-21.
[14] LI Y F, LI H J, GAO Q S, et al. Structural gray matter change early in male patients with HIV[J]. Int J Clin Exp Med, 2014, 7(10):3362-3369.
[15] THOMPSON P M, DUTTON R A, HAYASHI K M, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+T lymphocyte decline[J]. Proc Natl Acad Sci U S A, 2005, 102(43):15647-15652.
[16] SANFORD R, FELLOWS L K, ANCES B M, et al. Association of brain structure changes and cognitive function with combination antiretroviral therapy in HIV-positive individuals[J]. JAMA Neurol, 2018, 75(1):72-79.
[17] ANCES B M, ORTEGA M, VAIDA F, et al. Independent effects of HIV, aging, and HAART on brain volumetric measures[J]. J Acquir Immune Defic Syndr, 2012, 59(5):469-477.
[18] UNDERWOOD J, COLE J H, CAAN M, et al. Gray and white matter abnormalities in treated human immunodeficiency virus disease and their relationship to cognitive function[J]. Clin Infect Dis, 2017, 65(3):422-432.
[19] TESIC T, BOBAN J, BJELAN M, et al. Basal ganglia shrinkage without remarkable hippocampal atrophy in chronic aviremic HIV-positive patients[J]. J Neurovirol, 2018, 24(4):478-487.
[20] CLIFFORD K M, SAMBOJU V, COBIGO Y, et al. Progressive brain atrophy despite persistent viral suppression in HIV patients older than 60 years[J]. J Acquir Immune Defic Syndr, 2017, 76(3):289-297.
[21] VAN ZOEST R A, UNDERWOOD J, DE FRANCESCO D, et al. Structural brain abnormalities in successfully treated HIV infection:associations with disease and cerebrospinal fluid biomarkers[J]. J Infect Dis, 2017, 217(1):69-81.
[22] NIR T M, JAHANSHAD N, CHING C R K, et al. Progressive brain atrophy in chronically infected and treated HIV+individuals[J]. J Neurovirol, 2019, 25(3):342-353.
[23] CARDENAS V A, MEYERHOFF D J, STUDHOLME C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy[J]. J Neurovirol, 2009, 15(4):324-333.
[24] CORRÊA D G, ZIMMERMANN N, TUKAMOTO G, et al. Longitudinal assessment of subcortical gray matter volume, cortical thickness, and white matter integrity in HIV-positive patients[J]. J Magn Reson Imaging, 2016, 44(5):1262-1269.
[25] CORRÊA D G, ZIMMERMANN N, VENTURA N, et al. Longitudinal evaluation of resting-state connectivity, white matter integrity and cortical thickness in stable HIV infection:Preliminary results[J]. Neuroradiol J, 2017, 30(6):535-545.
[26] SANFORD R, ANCES B M, MEYERHOFF D J, et al. Longitudinal trajectories of brain volume and cortical thickness in treated and untreated primary human immunodeficiency virus infection[J]. Clin Infect Dis, 2018, 67(11):1697-1704.
[27] CHANG L, SHUKLA D K. Imaging studies of the HIV-infected brain[J]. Handb Clin Neurol, 2018, 152:229-264.
[28] DAHNKE R, YOTTER R A, GASER C. Cortical thickness and central surface estimation[J]. Neuroimage, 2013, 65:336-348.
[29] ASHBURNER J, FRISTON K J. Unified segmentation[J]. Neuroimage, 2005, 26(3):839-851.
[30] CAI W Q, WANG Y J. Advances in construction of human brain atlases from magnetic resonance images[J]. Chinese J Magn Reson, 2020, 37(2):241-453.蔡文琴,王远军.基于磁共振成像的人脑图谱构建方法研究进展[J].波谱学杂志, 2020, 37(2):241-253.
[31] CASTELO J M, COURTNEY M G, MELROSE R J, et al. Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise[J]. Arch Neurol, 2007, 64(9):1275-1280.
[32] HEAPS J M, SITHINAMSUWAN P, PAUL R, et al. Association between brain volumes and HAND in cART-naïve HIV+individuals from Thailand[J]. J Neurovirol, 2015, 21(2):105-112.
[33] WILSON T W, HEINRICHS-GRAHAM E, BECKER K M, et al. Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adults[J]. Hum Brain Mapp, 2015, 36(3):897-910.
[34] CORRÊA D G, ZIMMERMANN N, NETTO T M, et al. Regional cerebral gray matter volume in HIV-positive patients with executive function deficits[J]. J Neuroimaging, 2016, 26(4):450-457.
[35] KÜPER M, RABE K, ESSER S, et al. Structural gray and white matter changes in patients with HIV[J]. J Neurol, 2011, 258(6):1066-1075.
[36] BECKER J T, MARUCA V, KINGSLEY L A, et al. Factors affecting brain structure in men with HIV disease in the post-HAART era[J]. Neuroradiology, 2012, 54(2):113-121.
[37] ZHOU Y W, LI R L, WANG X X, et al. Motor-related brain abnormalities in HIV-infected patients:a multimodal MRI study[J]. Neuroradiology, 2017, 59(11):1133-1142.
[38] ABE H, MEHRAEIN P, WEIS S. Degeneration of the cerebellar dentate nucleus and the inferior olivary nuclei in HIV-1-infected brains:a morphometric analysis[J]. Acta Neuropathol, 1996, 92(2):150-155.
[39] KLUNDER A D, CHIANG M C, DUTTON R A, et al. Mapping cerebellar degeneration in HIV/AIDS[J]. Neuroreport, 2008, 19(17):1655-1659.
[40] TOWGOOD K J, PITKANEN M, KULASEGARAM R, et al. Mapping the brain in younger and older asymptomatic HIV-1 men:frontal volume changes in the absence of other cortical or diffusion tensor abnormalities[J]. Cortex, 2012, 48(2):230-241.
[41] WILEY C A, MASLIAH E, MOREY M, et al. Neocortical damage during HIV infection[J]. Ann Neurol, 1991, 29(6):651-657.
[42] VALCOUR V, CHALERMCHAI T, SAILASUTA N, et al. Central nervous system viral invasion and inflammation during acute HIV infection[J]. J Infect Dis, 2012, 206(2):275-282.
[43] GRAY F, SCARAVILLI F, EVERALL I, et al. Neuropathology of early HIV-1 infection[J]. Brain Pathol, 1996, 6(1):1-15.
[44] OZDENER H. Molecular mechanisms of HIV-1 associated neurodegeneration[J]. J Biosci, 2005, 30(3):391-405.
[45] SARMA M K, NAGARAJAN R, KELLER M A, et al. Regional brain gray and white matter changes in perinatally HIV-infected adolescents[J]. Neuroimage Clin, 2014, 4:29-34.
[46] HINKIN C H, VAN GORP W G, MANDELKERN M A, et al. Cerebral metabolic change in patients with AIDS:report of a six-month follow-up using positron-emission tomography[J]. J Neuropsychiatry Clin Neurosci, 1995, 7(2):180-187.
[47] ROTTENBERG D A, MOELLER J R, STROTHER S C, et al. The metabolic pathology of the AIDS dementia complex[J]. Ann Neurol, 1987, 22(6):700-706.
[48] ROTTENBERG D A, SIDTIS J J, STROTHER S C, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia[J]. J Nucl Med, 1996, 37(7):1133-1141.
[49] VAN GORP W G, MANDELKERN M A, GEE M, et al. Cerebral metabolic dysfunction in AIDS:findings in a sample with and without dementia[J]. J Neuropsychiatry Clin Neurosci, 1992, 4(3):280-287.
[50] VON GIESEN H J, ANTKE C, HEFTER H, et al. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits:electrophysiologic and positron emission tomography findings[J]. Arch Neurol, 2000, 57(11):1601-1607.
[51] HUA X, BOYLE C P, HAREZLAK J, et al. Disrupted cerebral metabolite levels and lower nadir CD4+counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment[J]. Neuroimage Clin, 2013, 3:132-142.
[52] KAUL M, GARDEN G A, LIPTON S A. Pathways to neuronal injury and apoptosis in HIV-associated dementia[J]. Nature, 2001, 410(6831):988-994.
[53] MATTSON M P, HAUGHEY N J, Nath A. Cell death in HIV dementia[J]. Cell Death Differ, 2005, 12(Suppl 1):893-904.
[54] ZHAO M L, KIM M O, MORGELLO S, et al. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis[J]. J Neuroimmunol, 2001, 115(1,2):182-191.
[55] ANTHONY I C, RAMAGE S N, CARNIE F W, et al. Influence of HAART on HIV-related CNS disease and neuroinflammation[J]. J Neuropathol Exp Neurol, 2005, 64(6):529-536.
[56] CHANG L, LEE P L, YIANNOUTSOS C T, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age[J]. Neuroimage, 2004, 23(4):1336-1347.
[57] SANFORD R, FERNANDEZ CRUZ A L, SCOTT S C, et al. Regionally specific brain volumetric and cortical thickness changes in HIV-infected patients in the HAART era[J]. J Acquir Immune Defic Syndr, 2017, 74(5):563-570.
[58] WRIGHT P W, PYAKUREL A, VAIDA F F, et al. Putamen volume and its clinical and neurological correlates in primary HIV infection[J]. Aids, 2016, 30(11):1789-1794.
[59] HEATON R K, FRANKLIN D JR R, DEUTSCH R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy:the longitudinal CHARTER study[J]. Clin Infect Dis, 2015, 60(3):473-480.
[60] BROUILLETTE M J, YUEN T, FELLOWS L K, et al. Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER cohort using group-based trajectory analysis[J]. PLoS One, 2016, 11(5):e0155766.
[61] SACKTOR N, SKOLASKY R L, SEABERG E, et al. Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study[J]. Neurology, 2016, 86(4):334-340.
[62] BONNET F, AMIEVA H, MARQUANT F, et al. Cognitive disorders in HIV-infected patients:are they HIV-related?[J]. Aids, 2013, 27(3):391-400.
[63] COLE J H, UNDERWOOD J, CAAN M W, et al. Increased brain-predicted aging in treated HIV disease[J]. Neurology, 2017, 88(14):1349-1357.
[64] COLE J H, CAAN M W A, UNDERWOOD J, et al. No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus:longitudinal neuroimaging results from the comorbidity in relation to AIDS (COBRA) project[J]. Clin Infect Dis, 2018, 66(12):1899-1909.
[65] YANG L Q, LIN F C, LEI H. Resting state functional connectivity in brain studied by fMRI approach[J]. Chinese J Magn Reson, 2010, 27(3):326-340.杨丽琴,林富春,雷皓.静息状态下脑功能连接的磁共振成像研究[J].波谱学杂志, 2010, 27(3):326-340.